These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 14581542)

  • 1. Contrasting use of CCR5 structural determinants by R5 and R5X4 variants within a human immunodeficiency virus type 1 primary isolate quasispecies.
    Yi Y; Singh A; Shaheen F; Louden A; Lee C; Collman RG
    J Virol; 2003 Nov; 77(22):12057-66. PubMed ID: 14581542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies.
    Singh A; Collman RG
    J Virol; 2000 Nov; 74(21):10229-35. PubMed ID: 11024154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordant utilization of macrophage entry coreceptors by related variants within an HIV type 1 primary isolate viral swarm.
    Singh A; Yi Y; Isaacs SN; Kolson DL; Collman RG
    AIDS Res Hum Retroviruses; 2001 Jul; 17(10):957-63. PubMed ID: 11461681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors.
    Pontow S; Ratner L
    J Virol; 2001 Dec; 75(23):11503-14. PubMed ID: 11689632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes.
    Yi Y; Shaheen F; Collman RG
    J Virol; 2005 Feb; 79(3):1480-6. PubMed ID: 15650174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
    Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
    Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.
    Gray L; Roche M; Churchill MJ; Sterjovski J; Ellett A; Poumbourios P; Sherieff S; Wang B; Saksena N; Purcell DF; Wesselingh S; Cunningham AL; Brew BJ; Gabuzda D; Gorry PR
    J Virol; 2009 Jun; 83(11):5430-41. PubMed ID: 19321618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
    Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
    J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma.
    Soulié C; Tubiana R; Simon A; Lambert-Niclot S; Malet I; Canestri A; Brunet C; Murphy R; Katlama C; Calvez V; Marcelin AG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):60-4. PubMed ID: 19390328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates.
    Chabot DJ; Zhang PF; Quinnan GV; Broder CC
    J Virol; 1999 Aug; 73(8):6598-609. PubMed ID: 10400757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants.
    Edo-Matas D; van Dort KA; Setiawan LC; Schuitemaker H; Kootstra NA
    Virology; 2011 Apr; 412(2):269-77. PubMed ID: 21295814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restricted replication of primary HIV-1 isolates using both CCR5 and CXCR4 in Th2 but not in Th1 CD4(+) T cells.
    Vicenzi E; Panina-Bodignon P; Vallanti G; Di Lucia P; Poli G
    J Leukoc Biol; 2002 Nov; 72(5):913-20. PubMed ID: 12429712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infection of cells expressing CXCR4 mutants lacking N-glycosylation at the N-terminal extracellular domain is enhanced for R5X4-dualtropic human immunodeficiency virus type-1.
    Thordsen I; Polzer S; Schreiber M
    BMC Infect Dis; 2002 Dec; 2():31. PubMed ID: 12489987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.
    Bunnik EM; Quakkelaar ED; van Nuenen AC; Boeser-Nunnink B; Schuitemaker H
    J Virol; 2007 Jan; 81(2):525-31. PubMed ID: 17079299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substitutions in a homologous region of extracellular loop 2 of CXCR4 and CCR5 alter coreceptor activities for HIV-1 membrane fusion and virus entry.
    Chabot DJ; Broder CC
    J Biol Chem; 2000 Aug; 275(31):23774-82. PubMed ID: 10827088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term evolution of transmitted CXCR4-using HIV-1 under effective antiretroviral therapy.
    Raymond S; Jeanne N; Nicot F; Lefebvre C; Carcenac R; Minier L; Chiabrando J; Cazabat M; Delobel P; Izopet J
    AIDS; 2019 Nov; 33(13):1977-1985. PubMed ID: 31259760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children.
    Cavarelli M; Karlsson I; Zanchetta M; Antonsson L; Plebani A; Giaquinto C; Fenyö EM; De Rossi A; Scarlatti G
    PLoS One; 2008 Sep; 3(9):e3292. PubMed ID: 18820725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of CCR5 use before and during coreceptor switching.
    Coetzer M; Nedellec R; Salkowitz J; McLaughlin S; Liu Y; Heath L; Mullins JI; Mosier DE
    J Virol; 2008 Dec; 82(23):11758-66. PubMed ID: 18815295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.